<!DOCTYPE html>
<html>
<head>
    <meta charset="utf-8">
    <link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/@picocss/pico@2/css/pico.classless.min.css">
    <title>Report 24-Sep-2025</title>
</head>
<body>
<main>
<a href="https://github.com/pathikrit/zeitgeist" target="_blank" rel="noopener" style="float: right;">
    <img src="https://github.githubassets.com/images/modules/logos_page/GitHub-Mark.png" alt="GitHub" width="30" height="30">
</a>
<h1>Daily Memo (24-Sep-2025)</h1>
<hr />
<h2>Key News Highlights</h2>
<ul>
<li><strong>Fed Cautions &amp; Market Valuation:</strong> Fed Chair Powell warns equities look &quot;fairly highly valued&quot; and flags inflation and slow hiring as ongoing challenges; indices slip in response.</li>
<li><strong>US Politics &amp; Policy Instability:</strong> Trump UN speech sharply criticizes EU allies and calls for aggressive NATO action if Russian aircraft violate airspace; cancels meetings with Democrats, raising shutdown risks.</li>
<li><strong>Russia-Ukraine War:</strong> Trump shifts stance, now claiming Ukraine could win against Russia, with additional calls for stronger NATO responses.</li>
<li><strong>Regulatory Scrutiny in Tech:</strong> Amazon’s trial over deceptive Prime subscription practices begins, while Apple’s and Amazon’s antitrust litigation risk is rising; OpenAI, Oracle, SoftBank announce major AI data center project expansions in Texas and other states.</li>
<li><strong>Healthcare &amp; Bio:</strong> Eli Lilly commits $6.5B to new Texas plant for obesity drugs. Alzheimer’s treatment advances draw global headlines; concern rises over drug-resistant “nightmare bacteria” spreading in the US.</li>
<li><strong>Climate &amp; Natural Disasters:</strong> Typhoon Ragasa causes major disruption in Taiwan, Hong Kong, and China; NASA launches urgent solar storm mission to protect infrastructure.</li>
<li><strong>Streaming &amp; Consumer Pricing:</strong> Disney+ to hike prices again, Apple’s iPhone 17 line earns strong early reviews.</li>
<li><strong>Labor Market Uncertainty:</strong> Obamacare subsidies at the center of budget showdown; H-1B visa overhaul for higher-paid workers proposed by Trump administration.</li>
</ul>
<hr />
<h2>Macro &amp; Policy Themes</h2>
<h3>US Economy, Rates, &amp; Fiscal Outlook</h3>
<ul>
<li><strong>Growth and Labor:</strong> US GDP growth for 2025 looks to be in the modest 1.1-2.5% band, with very low likelihood of recession or emergency rate moves in the next year. While some uptick in unemployment (&gt;4.2%) is likely by October 2025, outright recession risk for 2025 remains muted. Longer-term, sustained above-average unemployment (6-9%) by 2030 is more likely, potentially altering wage inflation dynamics later this decade.</li>
<li><strong>Inflation Dynamics:</strong> Core and headline inflation expected to persist in the 3-4% range through 2025, staying above the Fed's 2% target. Wage gains are set to outpace inflation in 2025, which could support continued consumer spending and broad index performance.</li>
<li><strong>Monetary Policy:</strong> Market does not expect significant Fed rate hikes or cuts in 2025; policy rates to stay range-bound, likely favoring intermediate-duration exposure over aggressive shifts to long duration. Rates above 3.25% into 2026 remain probable, putting a cap on high-growth tech but supporting cyclicals.</li>
<li><strong>Fiscal Directions:</strong> US debt set to breach $38T by end-2025, with new government spending increases near-certain regardless of rhetoric. Some risk of fiscal contraction under Trump, but substantial deep austerity is unlikely; the market expects continued large deficits even if spending cuts are pursued.</li>
<li><strong>Political &amp; Policy Risks:</strong> Policy volatility remains high, with credible (though not base case) risks of administration change, resignations, or impeachment. Uncertainty over US democracy indices and the fate of regulatory agencies (e.g., the Fed) create a persistent risk premium for US assets.</li>
<li><strong>Geopolitics &amp; FX:</strong> Little chance of major EU country exits this cycle, but modestly elevated risk of global recession in key developed markets (Japan, UK, Germany). Rising rhetoric over Ukraine and more hawkish US/NATO posturing toward Russia bear watching for energy and defense exposure.</li>
</ul>
<hr />
<h2>Sector Level Insights</h2>
<h3>Technology &amp; AI</h3>
<ul>
<li><strong>AI Sector:</strong> The expansion of large-scale AI infrastructure (OpenAI, Oracle, SoftBank projects) signals sustained capex demand through 2026. IPOs from OpenAI are expected before Anthropic, reinforcing focus and capital allocation toward the top AI name. Antitrust actions pose growing medium-term risk to both Amazon and Apple, and litigation surrounding AI liability (including tort damages for OpenAI and media lawsuits) is a rising technical and regulatory overhang.</li>
<li><strong>Cloud &amp; Data Centers:</strong> Investment in data center infrastructure remains robust, beneficial for hardware and REITs with significant hyperscale or cloud exposure.</li>
<li><strong>Tech Valuation &amp; Leadership:</strong> Despite strong sector performance, Fed warnings on overvaluation and historically high index levels (S&amp;P and Nasdaq) suggest caution on additional upside in absence of strong earnings growth.</li>
</ul>
<h3>Financials</h3>
<ul>
<li><strong>Banking Leadership:</strong> JPMorgan CEO succession is in play, with Marianne Lake a leading internal candidate. Fintech IPOs (Ramp expected ahead of Brex) indicate a favorable environment for private-to-public transitions but also intensify competitive threat to legacy banks.</li>
<li><strong>Crypto Corporate Adoption:</strong> The push for more S&amp;P 500 companies to hold bitcoin is increasing, supporting a floor under corporate crypto allocations.</li>
</ul>
<h3>Healthcare &amp; Biotech</h3>
<ul>
<li><strong>Drug Manufacturing:</strong> Eli Lilly’s Texas investment highlights continued growth in pharmaceuticals, obesity treatment, and active pharma ingredients—beneficial for life science and medtech suppliers.</li>
<li><strong>Infectious Disease:</strong> Spikes in drug-resistant bacteria are likely to increase demand for new antibiotics and infection control; no near-term breakthrough for Type 1 diabetes cure expected.</li>
</ul>
<h3>Energy, Renewables, &amp; Utilities</h3>
<ul>
<li><strong>Fossil Fuels Dominance:</strong> Oil and coal retention as top global primary energy sources through 2030 remains the highest probability, dampening the pace of renewables’ displacement.</li>
<li><strong>Clean Energy:</strong> US solar installs will grow steadily, but large jumps are not imminent; watch for continued incremental gains in capacity, supporting selective utilities/renewables investments over pure-play disruptors.</li>
<li><strong>Tesla Energy:</strong> Moderate expansion of Tesla’s energy storage business is increasingly likely, but breakthrough scale or affordable EV launches before 2027 remain low probability.</li>
</ul>
<h3>Consumer &amp; Media</h3>
<ul>
<li><strong>Streaming &amp; Content:</strong> Higher Disney+ prices, Apple’s new hardware, and strong streaming content pipeline (e.g., &quot;Last of Us&quot; S3 by 2027) support robust consumer digital spend, though pricing power could be tested in a higher unemployment or inflation environment.</li>
<li><strong>Antitrust Pressure:</strong> Regulatory pressure in tech/consumer (Amazon, Apple, Live Nation) is rising, which may result in forced changes to business practices or fines.</li>
</ul>
<hr />
<h2>Company-Specific/Tradeable Insights</h2>
<ul>
<li><strong>Tesla:</strong> Auto delivery growth and energy storage upside will likely be incremental, not explosive. No affordable EV breakthrough or large-scale robotics launch expected before 2027. Some leadership/succession risk for Elon Musk persists but does not dominate near-term outlook.</li>
<li><strong>Amazon &amp; Apple:</strong> Both face high probability of facing legal findings as monopolies within five years; operational headwinds likely from both litigation and ongoing regulatory scrutiny.</li>
<li><strong>OpenAI:</strong> Legal and regulatory risks remain significant, with likely multimillion-dollar exposures to damages or settlements.</li>
<li><strong>JPMorgan:</strong> CEO transition will be key; leadership continuity risk remains nontrivial.</li>
<li><strong>Live Nation:</strong> High odds of monopoly ruling; future M&amp;A, spin-outs, or regulatory-imposed operational changes possible.</li>
<li><strong>Eli Lilly:</strong> Major capex and product expansion in obesity and diabetes care set to underpin sustained revenue growth.</li>
</ul>
<hr />
<h2>Tactical/Strategic Takeaways</h2>
<ul>
<li><strong>Equity Indices:</strong> S&amp;P 500 and Nasdaq have more upside remaining this year, with moderate to high confidence of a positive close, but rate and valuation warnings from the Fed should temper aggressive chasing. Downside cases (&lt;5,000 in S&amp;P) appear very unlikely barring a macro shock.</li>
<li><strong>Rates &amp; Fixed Income:</strong> Intermediate rates will likely stay in a broad range through 2026, with limited rate hike or cut events on the horizon; inflation-protected strategies remain relevant given sticky inflation.</li>
<li><strong>Energy &amp; Commodities:</strong> Fossil fuels retain dominance in the global energy mix, so don't overweight immediate renewables displacement.</li>
<li><strong>Crypto:</strong> Corporate bitcoin allocations could see incremental growth, supporting the narrative for crypto in treasury management.</li>
<li><strong>Geopolitics:</strong> Russia-Ukraine risks remain, but peace or a decisive outcome looks unlikely for 2025; ongoing instability could continue to affect commodities, FX, and defense stocks.</li>
</ul>
<hr />
<p><em>Monitor for further escalation in regulatory actions on megacap tech, labor market weakness, new health risks, and geopolitical shocks, as these would drive significant recalibration of positioning.</em></p>

</main>
</body>
</html>
